Metabolic effects of combined hormonal contraception and a risk for thrombotic events


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To make a systematic review of the data available in the literature on the effect of combined oral contraceptives with different progestogenic components on the risk of venous and arterial thrombosis. Material and methods. For analysis, foreign and Russian publications were sought in the international system Pubmed over the past 15 years. Results. Risk factors for thrombotic events in women are described; differences in the influence of risk factors for venous or arterial thrombosis are analyzed. The data available in the literature on the role of progestin as part of combined hormonal contraceptives are discussed in the context of the occurrence of arterial or venous thrombosis. Progestins that have demonstrated the most favorable safety profile as part of combined contraceptives are mentioned. Conclusion. The need for a differentiated approach to identifying a risk for arterial and venous thrombosis in women using combined hormonal contraceptives is emphasized.

Full Text

Restricted Access

About the authors

Irina V. Kuznetsova

Women’s Health Research Center, Research Department, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

MD, PhD, Chief Researcher

References

  1. Прилепская В.Н. Руководство по контрацепции. М.: МЕДпресс-информ; 2006. [Prilepskaya V.N. Contraceptive Guide. Moscow: MEDpress-inform; 2006. (in Russian)]
  2. Blanco-Molina A., Rota L.L., Di Micco P., Brenner B., Trujillo-Santos J., Ruiz-Gamietea A., Monreal M.; RIETE Investigators. Venous tromboembolism during pregnancy, postpartum or during contraceptive use. Thromb. Haemost. 2010; 103(2): 306-31.
  3. Sorensen H.T., Horvath-Puho E., Pedersen L., Baron J.A., Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20- year cohort study. Lancet. 2007; 370(9601): 1773-9.
  4. Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks. Products information updated to help women make informed decision about their choice of contraception. European Medicines Agency; 2014.
  5. Havrilesky L.J., Gierisch J.M., Moorman P.G., Coeytaux R.R., Urrutia R.P., Lowery W.J. et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid. Rep. Technol. Assess. (Full Rep.). 2013; (212): 1-514.
  6. Yang L., Kuper H., Sandin S., Margolis K.L., Chen Z., Adami H.O., Weiderpass E. Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stroke in a cohort study of middle-aged Swedish women. Stroke. 2009; 40(4): 1050-8.
  7. Lidegaard Ø., Løkkegaard E., Jensen A., Skovlund C.W., Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N. Engl. J. Med. 2012; 366(24): 2257-66.
  8. Ahrendt H.J., Makalovd D., Parke S., Mellinger U., Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/ levonorgestrel. Contraception. 2009; 80(5): 436-44.
  9. Virkus R.A., Løkkegaard E.C., Bergholt T., Mogensen U., Langhoff-Roos J., Lidegaard Ø. Venous thromboembolism in pregnant and puerperal women in Denmark 1995-2005. A national cohort study. Thromb. Haemost. 2011; 106(2): 304-9.
  10. Quist-Paulsen P., Næss I.A., Cannegieter S.C., Romundstad P.R., Christiansen S.C., Rosendaal F.R., Hammerstrom J. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica. 2010; 95(1): 119-25.
  11. Wang C., Li Y., Li H., Sun T., Jin G., Sun Z. et al. Increased risk of stroke in oral contraceptive users carried replicated genetic variants: a population-based case-control study in China. Hum. Genet. 2012; 131(8): 1337-44.
  12. Mantha S., Karp R., Raghavan V., Terrin N., Bauer K.A., Zwicker J.I. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012; 14: e4944.
  13. Lowe G.D. Common risk factors for both arterial and venous thrombosis. Br. J. Haematol. 2008; 140(5): 488-95.
  14. Franchini M., Mannucci P.M. Venous and arterial thrombosis: different sides of the same coin? Eur. J. Intern. Med. 2008; 19(7): 476-81.
  15. Pomp E.R., Rosendaal F.R., Doggen C.J. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am. J. Hematol. 2008; 83(2): 97-102.
  16. Brækkan S.K., Mathiesen E.B., Njølstad I., Wilsgaard T., Størmer J., Hansen J.B. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromsp study. J. Thromb. Haemost. 2008; 6(11): 1851-7.
  17. MacGregor E.A. Contraception and headache. Headache. 2013; 53(2): 247-76.
  18. Martin K.A., Douglas P.S. Risk and side effects associated with estrogen-progestin contraceptives. Up to Date 2009 Jun [online] [access 2009 Sep]. Available at: http://www.utdol.com
  19. James A.H. Pregnancy-associated thrombosis. Hematology Am. Soc. Hematol. Educ. Program. 2009: 277-85.
  20. Bitzer J., Amy J.J., Beerthuizen R., Birkhäuser M., Bombas T., Creinin M. et al. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. Eur. J. Contracept. Reprod. Health Care. 2013; 18(3): 143-7.
  21. Sitruk-Ware R., Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract. Res. Clin. Endocrinol. Metab. 2013; 27(1): 13-24.
  22. Jick S.S., Jick H. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. Contraception. 2006; 74(2): 290-2.
  23. Blickstein I. Thrombophilia and women’s health: an overview. Obstet. Gynecol. Clin. North Am. 2006; 33(3): 347-56.
  24. Parkin L., Sharpies K., Hernandez R.K., Jick S.S. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011; 342: d2139.
  25. Martinez F., Ramírez I., Pérez-Campos E., Latorre K., Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur. J. Contracept. Reprod. Health Care. 2012; 17(1): 7-29.
  26. van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J., Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339: b2921.
  27. Reid R.L., Fortier M.P., Smith L., Mirkin S., Grubb G.S., Constantine G.D. Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception. 2010; 82(6): 497-502.
  28. Dinger J.C., Heinemann L.A.J., Kühl-Habich D. The safety of a drospiri-none-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142475 women-years of observation. Contraception. 2007; 75(5): 344-54.
  29. Sehovic N., Smith K.P. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products. Ann. Pharmacother. 2010; 44(5): 898-903.
  30. Dhont M., Verhaeghe V. Hormonal anticonception anno 2013: a clinician’s view. Facts Views Vis. Obgyn. 2013; 5(2): 149-59.
  31. Zahradnik H.P., Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) - an open-label, prospective, noncontrolled, office-based Phase III study. Contraception. 2008; 77(5): 337-43.
  32. Winkler U.H., Röhm P., Höschen K. An openlabel, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables. Contraception. 2010; 81(5): 391-400.
  33. Canonico M., Oger E., Plu-Bureau G., Conard J., Meyer G., Lévesque H. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115(7): 840-5.
  34. Canonico M., Alhenc-Gelas M., Plu-Bureau G., Olié V., Scarabin P.Y. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause. 2010; 17(6): 1122-7.
  35. EMA/607314/2013. PRAC confirms that benefits of all combined hormonal contraceptives (CHCs) continue to outweigh risks. 11. October 2013. Available at: http://www.ema.europa.eu
  36. Kerscher M., Reuther T., Krueger N., Buntrock H. Effects of an oral contraceptive containing chlormadinone acetate and ethinylestradiol on hair and skin quality in women wishing to use hormonal contraception. J. Eur. Acad. Dermatol. Venereol. 2013; 27(5): 601-8.
  37. Арефьева М. Тромботический риск при использовании гормональных контрацептивов. Медицинские аспекты здоровья женщины. 2013; 69(5): 66-70. [Arefeva M. Thrombotic risk when using hormonal contraceptives. Meditsinskie aspektyi zdorovya zhenschinyi. 2013; 69(5): 66-70. (in Russian)]
  38. Stegeman B.H., Helmerhorst F.M., Vos H.L., Rosendaal F.R., Van Hylckama Vlieg A. Sex hormone-binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives. J. Thromb. Haemost. 2012; 10(10): 2061-7.
  39. Stegeman B.H., Raps M., Helmerhorst F.M., Vos H.L., van Vliet H.A., Rosendaal F.R., van Hylckama Vlieg A. Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone-binding globulin levels in premenopausal women. J. Thromb. Haemost. 2013; 11(1): 203-5.
  40. De Groote D., Perrier d’Hauterive S., Pintiaux A., Balteau B., Gerday C., Claesen J., Foidart J.M. Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18-35 years old. Contraception. 2009; 80(2): 187-93.
  41. Uras R., Orrù M., Etzi R., Peppi G., Marotto M.F., Pilloni M. et al. Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass. Contraception. 2009; 79(2): 117-21.
  42. Franceschini S.A., Vieira C.S., Martins W.P., França J.B., Ferriani R.A. Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium. Contraception. 2013; 87(6): 766-72.
  43. Ziller M., Ziller V., Haas G., Rex J., Kostev K. Risk of venous thrombosis in users of hormonal contraceptives in German gynaecological practices: a patient database analysis. Arch. Gynecol. Obstet. 2014; 289(2): 413-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies